Blood test markers in new acute lymphoblastic leukemia cases
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at simple blood test results from people newly diagnosed with acute lymphoblastic leukemia (ALL) to see if certain markers help understand the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be newly diagnosed with acute lymphoblastic leukemia (ALL)
- Cannot have any other type of cancer
- Must not have started treatment for ALL yet
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures two simple blood markers (SII and CAR) in people newly diagnosed with acute lymphoblastic leukemia (ALL) who haven't started treatment yet. The goal is to see if these markers can help guide care.
This study looks at whether certain blood cell tests (reticulocyte parameters) can early detect how well your bone marrow is making red blood cells in people newly diagnosed with chronic B-cell cancers. It aims to improve monitoring before standard treatments begin.
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
This study looks at whether a simple blood test can help track how well treatment is working in children with leukemia. It may help doctors understand the disease better and guide future care.
This study looks at a special blood test that measures cell-free DNA (tiny pieces of genetic material) in children with acute lymphoblastic leukemia (ALL). It aims to understand how this test might help monitor the disease, and it is for newly diagnosed children who haven't started treatment yet.
This study examines specific markers (PD-L1 and CD276) on blood cancer cells in newly diagnosed patients with B-cell leukemias or lymphomas. Understanding these markers may help doctors better understand your cancer and develop better treatments.
Hear when a new Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.